GSK joins a crowd of phar­ma com­pa­nies re­strict­ing sales un­der fed­er­al pro­gram

Glax­o­SmithK­line re­cent­ly be­came the 14th bio­phar­ma com­pa­ny to switch up its ap­proach to dis­trib­ut­ing drugs pur­chased via the fed­er­al 340B pro­gram for low-in­come in­di­vid­u­als. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER